The treatment of advanced lung adenocarcinoma with activating EGFR mutations

References

• Bethune G, Bethune D, Ridgway N, et al. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48–51.
   PubMedGoogle Scholar
• Hynes NE, Watson CJ. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol. 2010;2(8):a003186.
   PubMed Web of Science ®Google Scholar
• Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):110–118.
   PubMed Web of Science ®Google Scholar
• Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10(3):242–248.
   PubMed Web of Science ®Google Scholar
• Stewart EL, Tan SZ, Liu G, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67–81.
   PubMed Web of Science ®Google Scholar
• Rocco D, Battiloro C, Della Gravara L, et al. Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first line treatment and beyond. Rev Recent Clin Trials. 2019;14(2):120–128. . PMID: 30520383.
   PubMed Web of Science ®Google Scholar
• Ridge CA, McErlean AM, Ginsberg MS, et al. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30(2):93–98.
   PubMed Web of Science ®Google Scholar
• de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–233.
   PubMed Web of Science ®Google Scholar
• Schabath MB, Michele L. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Oct 1;28(10):1563–1579.
   Google Scholar
• Bubendorf L, Lantuejoul S, de Langen AJ, et al. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. Eur Respir Rev. Jun 2017;26(144):170007.
   PubMed Web of Science ®Google Scholar
• Gower A, Wang Y, Giaccone G, et al. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl). 2014;92(7):697–707.
   PubMed Web of Science ®Google Scholar
• Griffin R, Ramirez RA. Molecular targets in non-small cell lung cancer. Ochsner J. 2017;17(4):388–392.
   PubMed Web of Science ®Google Scholar
• Zhou S, Wang H, Jiang W, et al. Clinicopathological characteristics and EGFR-TKIs efficacies in lung squamous cell carcinoma patients harboring an EGFR sensitizing mutation. Onco Targets Ther. 2019;12:8863–8871. Published 2019 Oct 30.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar;1(3):231–239. PMID: 17409862.
   PubMed Web of Science ®Google Scholar
• Leduc C, Merlio JP, Besse B, et al. Clinical and molecular characteristics of non-small-celllung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative ThoracicIntergroup (IFCT) programAnn Oncol. 2017;28:2715–2724. Published online 28 July 2017.
   Google Scholar
• Solassol I, Pinguet F, Quantin X, et al. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019;9(11):668. Published 2019 Oct 30.
   PubMed Web of Science ®Google Scholar
• FDA approves dacomitinib for metastatic non-small cell lung cancer. fda.gov [Internet]. [cited 2020 Oct]. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0.
   Google Scholar
• Vizimpro/dacomitinib. ema.europa.eu [Internet]. [cited 2020 Oct]. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro.
   Google Scholar
• FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC. fda.gov [Internet]. [cited 2020 Oct]. available at:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc.
   Google Scholar
• Cyramza/ramucirumab summary of opinion. ema.europa.eu [Internet]. [cited 2020 Oct]. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cyramza-ii-33_en.pdf.
   Google Scholar
• Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018 Sep;6(9):681–690. Epub 2018 Jul 17. Erratum in: Lancet Respir Med. 2018 Sep;6(9):e50.PMID: 30017884.
   PubMed Web of Science ®Google Scholar
• Oellerich M, Christenson RH, Beck J, et al. Plasma EGFR mutation testing in non-small cell lung cancer: a value proposition. Clin Chim Acta. 2019 Aug;495: 481–486. Epub 2019 May 21. PMID: 31125533.
   PubMed Web of Science ®Google Scholar
• Malapelle U, Raez LE, Serrano MJ, et al. International society of liquid biopsies (ISLB). Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. J Thorac Dis. 2018;10(12):6388–6391.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246. Epub 2012 Jan 26. PMID: 22285168.
   PubMed Web of Science ®Google Scholar
• Leon LF, Golsorkhi A, Liu S, et al. 1273P - overall survival analyses of first-line erlotinib versus chemotherapy in the eurtac study population controlling for the use of post-study therapy. Ann Oncol. Sept 2014;25(4):iv447.
   Google Scholar
• Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec 01;20(12):1655–1669.
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014. DOI:https://doi.org/10.1016/S1470-2045(14)70381-X
   Google Scholar
• Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J Clin Oncol. 2018;(suppl):abstr 9007. DOI:https://doi.org/10.1200/JCO.2018.36.15_suppl.9007. Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 9007-9007.
   Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866–2874. . Epub 2011 Jun 13. PMID: 21670455.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb 01;16(2):141–151.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454–1466. . Epub 2017 Sep 25. PMID: 28958502.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Cheng Y, Zhou X, et al. Updated overall survival (OS) from extended follow up in ARCHER1050: a randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations. Ann Oncol. 2019 Nov 01;30(SUPPLEMENT 9):ix200–ix201.
   Google Scholar
• Biswas B, Ganguly S, Ghosh J, et al. Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: a single center experience from India. J Clin oncol. 2021;39(15_suppl):e21043–e21043.
   Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC January 2, 2020. N Engl J Med. 2020;382. 41–50.
   PubMed Web of Science ®Google Scholar
• Del Re M, Crucitta S, Gianfilippo G, et al. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Int J Mol Sci. 2019;20(16):3951. . Published 2019 Aug 14.
   Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer February 16, 2017. N Engl J Med. 2017;376:629–640.
   PubMed Web of Science ®Google Scholar
• Wu Y, Mok TSK, Han J, et al. Overall survival (OS) from the AURA3 phase III study: osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). Ann Oncol. 2019;30(suppl_9):ix157–ix181.
   Google Scholar
• Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740–763. . Epub 2020 Dec 15. PMID: 33338652.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Kudoh S, Mitsuoka S, et al. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer. 2015;90(1):65–70.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266.
   PubMed Web of Science ®Google Scholar
• Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int J Cancer. 2017;141(6):1249–1256.
   PubMed Web of Science ®Google Scholar
• Oizumi S, Sugawara S, Minato K, et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018;3(2):e000313.
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al. North-East Japan study group. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020 Jan 10;38(2):115–123. . Epub 2019 Nov 4. PMID: 31682542.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(4):465–469.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302–316.
   PubMed Web of Science ®Google Scholar
• FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations. fda.gov [internet]. [cited 2021 Mar]. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr.
   Google Scholar
• Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):45–51.
   PubMed Web of Science ®Google Scholar
• Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17(3):237–245.
   PubMed Web of Science ®Google Scholar
• Gristina V, Malapelle U, Galvano A, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev. 2020;85:101994. 0305-7372.
   PubMed Web of Science ®Google Scholar
• Cho JH, Lim SH, Jung H, et al. An osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin oncol. 2020;38(5):488–495.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: eSMOClinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement 4):iv192–iv237.
   PubMedGoogle Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline. UpdateJournal of Clinical Oncology. 2017;35(30):3484–3515.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology non-small cell lung cancer. NCCN.org [internet]. [cited 2020 Oct]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Leonetti A, Facchinetti F, Tiseo M, et al. Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?. Ann Transl Med. 2018;6(Suppl 2):S110.
   PubMedGoogle Scholar
• Remon J, Lopes G. Upfront osimertinib - winner takes it all?. Nat Rev Clin Oncol.2020 Apr; 17(4):202–203. . PMID: 32112056.
   PubMed Web of Science ®Google Scholar
• Lamberti G, Andrini E, Ricciuti B, et al. Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. J Thorac Dis. 2019;11(Suppl S15):S1831–S1834.
   PubMedGoogle Scholar
• Kato Y, Hosomi Y, Watanabe K, et al. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2019;11(6):2350–2360.
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737.
   PubMed Web of Science ®Google Scholar
• Lazzari C, Gregorc V, Karachaliou N, et al. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12(5):2851–2858.
   PubMed Web of Science ®Google Scholar
• Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. Nov 2019;137:149–156.
   PubMed Web of Science ®Google Scholar
• Piper-Vallillo AJ, Sequist LV, Piotrowska Z, et al. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38(25):2926–2936.
   Web of Science ®Google Scholar
• Phase 2 platform study in patients with advanced non-small lung cancer who progressed on first-line osimertinib therapy (ORCHARD) (ORCHARD). clinicaltrials.org [internet].ClinicalTrials.gov Identifier: NCT03944772. [cited 2020 Oct]. Available at:https://www.clinicaltrials.gov/ct2/show/NCT03944772.
   Google Scholar
• Osimertinib plus savolitinib in EGFRm+/MET+ NSCLC following prior osimertinib (SAVANNAH). clinicaltrials.org [internet]. ClinicalTrials.gov Identifier: NCT03778229. [cited 2020 Oct]. Available at:https://www.clinicaltrials.gov/ct2/show/NCT03778229.
   Google Scholar
• A study of tepotinib plus osimertinib in osimertinib relapsed mesenchymal-epithelial transition factor (MET) amplified non-small cell lung cancer (NSCLC) (INSIGHT 2) (INSIGHT 2). clinicaltrials.org [internet]. ClinicalTrials.gov Identifier: NCT03940703. [cited 2020 Oct]. Available at: https://clinicaltrials.gov/ct2/show/NCT03940703.
   Google Scholar
• Leilei W, Linping K, Zhenshan Z, et al. Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors. Front Oncol. 2020;10:2778.
   Web of Science ®Google Scholar
• Rocco D, Della Gravara L, Battiloro C, et al. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Rev Anticancer Ther. 2019 Jul;19(7):561–568. . Epub 2019 Jun 25. PMID: 31188040.
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019 May;7(5):387–401. . Epub 2019 Mar 25. PMID: 30922878.
   PubMed Web of Science ®Google Scholar
• Della Gravara L, Battiloro C, Cantile R, et al. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?. Lung Can Manag. 2020;9(1):LMT22. DOI:https://doi.org/10.2217/lmt-2019-0018
   Google Scholar
• White M, Neal JW, Gardner RM, et al. Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. J Thorac Oncol. 2021;16(suppl_4):S748–S802.
   Web of Science ®Google Scholar
• Study of pemetrexed + Platinum chemotherapy with or without pembrolizumab (MK-3475) in adults with tyrosine kinase inhibitor- (TKI)-resistant epidermal growth factor receptor- (EGFR)-mutated metastatic non-squamous non-small cell lung cancer (NSCLC) (MK-3475-789/KEYNOTE-789). clinicaltrials.org [internet]. ClinicalTrials.gov Identifier: NCT03515837. [cited 2021 Jul]. Available at:https://clinicaltrials.gov/ct2/show/NCT03515837.
   Google Scholar
• A study of nivolumab + chemotherapy or nivolumab + ipilimumab versus chemotherapy in non-small cell lung cancer (NSCLC) participants with epidermal growth factor receptor (EGFR) mutation who failed 1L or 2L EGFR tyrosine kinase inhibitor (TKI) therapy (checkMate722). clinicaltrials.org [internet]. ClinicalTrials.gov Identifier: NCT02864251. [cited 2021 Jul]. Available at:https://clinicaltrials.gov/ct2/show/NCT02864251.
   Google Scholar